API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
NST-4016 (icosabutate), is a once-daily, oral SEFA currently in Phase 2b clinical trial for non-alcoholic steatohepatitis. It has demonstrated dose-dependent and significant improvements in all liver function parameters as well as in inflammatory and fibrotic biomarkers.
Lead Product(s): Icosabutate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: NST-4016
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile.
Lead Product(s): Icosabutate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: NST-4016
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2021
Details:
Proceeds will be used to progress the SEFA development pipeline: Completion of Ph 2b study of lead programme Icosabutate in (NASH) Initiation of clinical development of two new programmes for (PNALD)
Lead Product(s): Icosabutate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: venBio Partners
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 08, 2020